Register for our free email digests:
Merck BioVentures
Division of Merck & Co. Inc.
www.merck.com
Latest From Merck BioVentures
Hanwha In Talks For Enbrel Biosimilar Deal
Germany’s Merck is one of the multinationals said to be in negotiations with the South Korean firm Hanwha over the possible licensing of a biosimilar version of Amgen’s blockbuster rheumatoid arthritis treatment Enbrel and/or related technology.
Hanwha Biologics CEO Paul Coleman On Developing Biosimilars In Korea: An Interview With PharmAsia News (Part 1 of 2)
The former Biogen Idec exec sits down to talk about Hanwha’s biosimilars strategy and pipeline, and why its deal fell apart with Merck to develop a biosimilar of Enbrel.
Deals Of The Week Wonders: What Does Merck’s Latest Biosimilar Move Really Mean?
Plus a look at Roche/Chiasma, Chiesi/Cornerstone, Eisai/Valeant and more
“The Pink Sheet” – Most Notable Stories Of 2012
Developments in off-label enforcement and scrutiny of economic superiority claims, new approaches to R&D, and biosimilars are among issues that captured readers’ attention last year.
Company Information
- Industry
- Pharmaceuticals
- Therapeutic Areas
- Non-Specific
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Merck & Co. Inc.
- Senior Management
- Contact Info
-
Merck BioVentures
One Merck Dr.
Whitehouse Station, NJ 08889
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice